Prabotulinumtoxin A clinical trials
Also written prabotulinumtoxinA, Jeuveau, ABP-450 and DWP450.
A product of Botulinum toxin type A; its studies count on that page too.
How each study uses prabotulinumtoxin A is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the prabotulinumtoxin A studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 1 Feb 2019 · Jeuveau · BLA 761085 (FDA, Purple Book)
- European Union
- 27 Sept 2019 · Nuceiva · EMEA/H/C/004587 (EMA; as botulinum toxin type A)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
17 studies that test it; most in 2021 (6); 1 more planned to start later
| Year | Studies |
|---|---|
| 2015 | 2 |
| 2020 | 3 |
| 2021 | 6 |
| 2022 | 3 |
| 2023 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 9
AEON Biopharma, Inc. (4) · Daewoong Pharmaceutical Co. LTD. (3) · Yonsei University (2) · Evolus, Inc. (2) · University of Southern California (1) · Recep Tayyip Erdogan University (1) · University of Pennsylvania (1) · Lupo Center for Aesthetic and General Dermatology (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- A dosage form of Botulinum toxin type A source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test prabotulinumtoxin A.
- Mar 2027BoTox Into the Sternocleidomastoid Muscles (SCM)Phase 4 · Boston Medical Center
Studies
Open first, then newest update. How each study uses prabotulinumtoxin A is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 18
- BoTox Into the Sternocleidomastoid Muscles (SCM)RecruitingPhase 4Boston Medical CenterNCT06903975Written as prabotulinumtoxinA-xvfs
- Study of DWP450 in Japanese Subjects With Glabellar LinesNot yet recruitingPhase 3Daewoong Pharmaceutical Co. LTD.NCT07783763Written as DWP450 20 U
- Comparison of Dry Needling and Two Botulinum Toxins for BruxismCompletedNot applicableRecep Tayyip Erdogan UniversityNCT07452510Written as PrabotulinumtoxinA
- A Study Comparing the Safety, Efficacy, and Diffusion of Letibotulinum Toxin A Versus Other Botulinum Toxin Products in Adults With Moderate-to-Severe Forehead WrinklesCompletedPhase 4Yonsei UniversityNCT07072806Written as Prabotulinum toxin A
- Evaluation of Four Injectable Neuromodulators in the Glabella Area Glabella AreaCompletedNot applicableUniversity of PennsylvaniaNCT05167864Written as PrabotulinumtoxinA for Injection
- Extension Study of ABP-20001 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 for Migraine PreventionTerminatedPhase 2AEON Biopharma, Inc.NCT05016661Written as ABP-450
- Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in AdultsCompletedPhase 2AEON Biopharma, Inc.NCT04845178Written as ABP-450
- Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar LinesCompletedPhase 2Evolus, Inc.NCT05320393Written as PrabotulinumtoxinA-Xvfs
- Extension Study of ABP-19000 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 in Cervical DystoniaCompletedPhase 2AEON Biopharma, Inc.NCT04871451Written as ABP-450
- DWP450 for Treating Moderate to Severe Glabellar LinesCompletedPhase 3Daewoong Pharmaceutical Co. LTD.NCT06354127Written as DWP450
- Spread of PrabotulinumtoxinA-xvfs Versus OnabotulinumtoxinA in the Treatment of Forehead RhytidesCompletedEarly Phase 1Lupo Center for Aesthetic and General DermatologyNCT05807412Written as PrabotulinumtoxinA-Xvfs
- A Phase 2 Study to Evaluate the Safety and Efficacy of ABP-450 in the Treatment of Cervical DystoniaCompletedPhase 2AEON Biopharma, Inc.NCT04849988Written as ABP-450
- Jeuveau Treatment of Glabellar Lines Using OLD Versus COLDCompletedEarly Phase 1Clinical Testing of Beverly HillsNCT05129319Written as prabotulinumtoxinA
- Split-Face Study Comparing Botox and Jeuveau in Treating Glabellar LinesActive, not recruitingEarly Phase 1University of Southern CaliforniaNCT04715048Written as PrabotulinumtoxinA
- Efficacy of Prabotulinum and Onabotulinum Toxin-A for Facial WrinklesCompletedPhase 4Instituto de Oftalmología Fundación Conde de ValencianaNCT05840445Written as Prabotulinumtoxin A
- Efficacy and Safety of DWP450 in Subjects With Benign Masseteric HypertrophyCompletedPhase 3Daewoong Pharmaceutical Co. LTD.NCT04294251Written as DWP450
- Safety Study of DWP-450 (Botulinum Toxin, Type a) to Treat Glabellar Lines - EV-006CompletedPhase 2Evolus, Inc.NCT02428608Written as DWP-450 (Botulinum purified neurotoxin, Type A)
- Botulinum Toxin Type A Injection Into the Gastrocnemius Muscle for Treatment of Nocturnal Calf Cramps in Patients With Lumbar Spinal StenosisCompletedNot applicableYonsei UniversityNCT02444351Written as botulinum toxin type A (Nabota®) injection into the gastrocnemius muscle
Given beside what is tested · 1 — prabotulinumtoxin A is usual care or a partner of the new treatment
Codes
What other systems call prabotulinumtoxin A · ClinicalTrials.gg INT001089
- UNII (FDA) 0A6JH35GMQPRABOTULINUMTOXIN AOne source FDA
- RxNorm 2117869One source FDA
- NCI Thesaurus C175750Prabotulinumtoxin AOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 0A6JH35GMQ | PRABOTULINUMTOXIN A | One source FDA |
| RxNorm | 2117869 | — | One source FDA |
| NCI Thesaurus | C175750 | Prabotulinumtoxin A | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.